Partnering Opportunities
Virttu Biologics is well-positioned to play a significant role in the oncolytic immunotherapy field and welcomes interest from potential partners to further develop the lead product or platform technology. If you are interested in discussing partnering opportunities, please contact Virttu on admin@virttu.com
Technology
VIRTTU's lead programme SEPREHVIR®, a unique oncolytic immunotherapy, shows the potential to transform treatment and target many forms of cancer effectively.
Clinical Studies
We are conducting clinical studies in a wide range of cancer types in leading medical centres in the USA and Europe.